Moshe Fridman - Academia.edu (original) (raw)

Papers by Moshe Fridman

Research paper thumbnail of Factors Associated With Response to Growth Hormone in Pediatric Growth Disorders: Results of a 5-year Registry Analysis

Journal of the Endocrine Society

Context Growth hormone (GH) therapy can increase linear growth in patients with growth hormone de... more Context Growth hormone (GH) therapy can increase linear growth in patients with growth hormone deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), and Prader-Willi syndrome (PWS), although outcomes vary by disease state. Objective To assess growth and identify factors associated with growth response with long-term GH therapy. Methods Data from pediatric patients with GHD, TS, NS, and PWS obtained at GH treatment initiation (baseline) and annually for 5 years in the ANSWER Program and NordiNet® IOS were analyzed retrospectively. Height standard deviation score (HSDS) was assessed over time, and multivariate analyses determined variables with significant positive effects on growth outcomes in each patient cohort. Results Data from patients with GHD (n = 12 683), TS (n = 1307), NS (n = 203), and PWS (n = 102) were analyzed. HSDS increased over time during GH treatment in all cohorts. Factors with significant positive effects on ΔHSDS were younger age at GH initiation and lowe...

Research paper thumbnail of LBMON197 Predictors Of Response To Growth Hormone Treatment In Pediatric Growth Disorders: Analysis From The Answer Program And Nordinet® IOS

Journal of the Endocrine Society

Background The American Norditropin® Studies: Web-Enabled Research (ANSWER) Program and the Nordi... more Background The American Norditropin® Studies: Web-Enabled Research (ANSWER) Program and the NordiNet® International Outcome Study (NordiNet® IOS) were large-scale, non-interventional studies intended to gather long-term data on the effectiveness and safety of Norditropin® (somatropin) treatment in the real-world setting. Data were collected in the US and Europe from 2006 to 2016. Objective To determine predictors of response to daily growth hormone (GH) for height outcomes using a longitudinal analysis across 5 years of real-world data from pediatric patients with growth hormone deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), and Prader-Willi syndrome (PWS). Methods Data were combined for ANSWER and NordiNet® IOS studies for GH-treatment-naïve pediatric patients on daily somatropin. Descriptive statistics for baseline demographics, outcomes, and GH (mg/kg/d) data were analyzed for each indication; statistics for outcome and GH data were analyzed over time for absolute ...

Research paper thumbnail of Prospective multi-center phase II trial of docetaxel and vinorelbine with filgrastim support in subjects with advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology, 2004

7138 Background. Although platinum based chemotherapy (CT) regimens are the standard of therapy i... more 7138 Background. Although platinum based chemotherapy (CT) regimens are the standard of therapy in first line NSCLC, a subset of patients are ineligible to receive such agents. Docetaxel and vinorelbine are each active agents in NSCLC and when combined may provide enhanced activity. The purpose of this study was to evaluate the safety and efficacy of this combination therapy when administered on a Q2W schedule with Filgrastim support. METHODS This multi-center, community based study was conducted in 10 sites that enrolled 61 CT naïve patients with Stage IIIb/IV NSCLC. Treatment consisted of vinorelbine 45mg/m2and docetaxel 60mg/m2 D1 and Filgrastim 5 mcg/kg D2 -D14 repeated Q2W for 8 cycles. Patients were evaluated for response at the end of cycles 2, 5 and 8. Confirmed response was defined as complete or partial response (CR, PR) based upon two or more evaluations, while best response was defined as the best of the three evaluations. We report response rate and Kaplan-Meier estimate (95%CL) of time to disease progression and one-year survival. RESULTS Of 61 enrolled patients 42% (95% confidence interval [CI], 30% to 54%) achieved either CR or PR as best response; and 13% (95% CI, 9% to 17%) of patients had a confirmed response. Median time to disease progression was 160 days. With a median follow-up time of 14.2 months, the estimated median survival time is 14.1 months (95% CI lower bound, 8.5), and the 1-year survival rate is 57% (95% CI, 44% to 70%). Five patients (8%) experienced febrile neutropenia (ANC < 500/mm3 plus body temperature >= 38.2°C). Overall calculated dose intensity (delivered/planned dose x 100) was 95% for vinorelbine and 93% for docetaxel. CONCLUSION The combination of docetaxel and vinorelbine can be delivered with high dose intensity with Filgrastim support. Additionally in this multi-center non-controlled study completed in a community setting, an interesting 1-year and overall median survival is observed and supports further evaluation. [Table: see text].

Research paper thumbnail of Phase II trial of R-CHOP plus maintenance rituximab for previously untreated intermediate or high grade non-Hodgkin’s lymphoma (IHGNHL) with filgrastim support for older patients greater than 60 years

Journal of Clinical Oncology, 2005

6623 Introduction: R-CHOP is considered standard treatment (tx) for IHGNHL. Administering full do... more 6623 Introduction: R-CHOP is considered standard treatment (tx) for IHGNHL. Administering full doses of R-CHOP is crucial to maximize response. Older patients (pts) may experience a higher incidenc...

Research paper thumbnail of The Association of Shift-Level Nurse Staffing With Adverse Patient Events

JONA: The Journal of Nursing Administration, 2011

Research paper thumbnail of Community-Based Trial of R-CHOP and Maintenance Rituximab for Intermediate- or High-Grade Non-Hodgkin Lymphoma with First-Cycle Filgrastim for Older Patients

Clinical Lymphoma and Myeloma, 2007

Research paper thumbnail of Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma

Cancer, 2005

Vinorelbine and docetaxel are active single agents in the treatment of nonsmall cell lung carcino... more Vinorelbine and docetaxel are active single agents in the treatment of nonsmall cell lung carcinoma (NSCLC) and may provide enhanced activity when combined in a dose-dense fashion. The efficacy and safety of this combination was assessed when it was administered every 14 days with Filgrastim support in a community practice setting. This open-label study was conducted at 12 community oncology practices in the United States. Sixty-one chemotherapy-naive patients with Stage IIIB/IV NSCLC received vinorelbine 45 mg/m2 followed by docetaxel 60 mg/m2 on Day 1 and Filgrastim 5 mcg/kg beginning on Day 2, with cycles repeated every 14 days. Among 61 enrolled patients, 44% of patients had either a complete or partial response as their best response, and 27% of patients had confirmed complete or partial responses. The median time to confirmed response was 1.9 months (95% confidence interval [95% CI], 0.9-2.3 mos), and the median duration of confirmed response was 6.0 months (95% CI, 3.1-14.4 mos). The median time to disease progression was 4.9 months (95% CI, 3.8-5.8 mos). With a median follow-up of 14.3 months, the median survival was 12.9 months (95% CI, 8.1-14.3 mos), and the 1-year survival rate was 56% (95% CI, 43-69%). The relative dose intensity was 94% for vinorelbine and 93% for docetaxel. Febrile neutropenia occurred in 9 patients (15%) and during 9 of 351 cycles (3%). It was possible to administer dose-dense vinorelbine and docetaxel chemotherapy with Filgrastim support, beginning in the first cycle, to patients with NSCLC who were treated in a community practice setting.

Research paper thumbnail of Response to “A call for consideration of needlestick injury data in evaluating staffing effectiveness”

American Journal of Infection Control, 2012

Research paper thumbnail of Needlestick injuries among nursing staff: Association with shift-level staffing

American Journal of Infection Control, 2011

Research paper thumbnail of Capacity-Building for Collecting Patient-Reported Outcomes and Experiences (PRO) Data Across Hospitals

Maternal and Child Health Journal

Purpose Patient-reported outcomes and experiences (PRO) data are an integral component of health ... more Purpose Patient-reported outcomes and experiences (PRO) data are an integral component of health care quality measurement and PROs are now being collected by many healthcare systems. However, hospital organizational capacity-building for the collection and sharing of PROs is a complex process. We sought to identify the factors that facilitated capacity-building for PRO data collection in a nascent quality improvement learning collaborative of 16 hospitals that has the goal of improving the childbirth experience. Description We used standard qualitative case study methodologies based on a conceptual framework that hypothesizes that adequate organizational incentives and capacities allow successful achievement of project milestones in a collaborative setting. The 4 project milestones considered in this study were: (1) Agreements; (2) System Design; (3) System Development and Operations; and (4) Implementation. To evaluate the success of reaching each milestone, critical incidents were...

Research paper thumbnail of Factors Associated With Response to Growth Hormone in Pediatric Growth Disorders: Results of a 5-year Registry Analysis

Journal of the Endocrine Society

Context Growth hormone (GH) therapy can increase linear growth in patients with growth hormone de... more Context Growth hormone (GH) therapy can increase linear growth in patients with growth hormone deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), and Prader-Willi syndrome (PWS), although outcomes vary by disease state. Objective To assess growth and identify factors associated with growth response with long-term GH therapy. Methods Data from pediatric patients with GHD, TS, NS, and PWS obtained at GH treatment initiation (baseline) and annually for 5 years in the ANSWER Program and NordiNet® IOS were analyzed retrospectively. Height standard deviation score (HSDS) was assessed over time, and multivariate analyses determined variables with significant positive effects on growth outcomes in each patient cohort. Results Data from patients with GHD (n = 12 683), TS (n = 1307), NS (n = 203), and PWS (n = 102) were analyzed. HSDS increased over time during GH treatment in all cohorts. Factors with significant positive effects on ΔHSDS were younger age at GH initiation and lowe...

Research paper thumbnail of Reporting of Adverse Drug Reactions with Parenteral Drugs for the On-Demand Treatment of Hereditary Angioedema Attacks – Analysis of the FAERS Database 2009 to 2022

Journal of Allergy and Clinical Immunology

Research paper thumbnail of The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata

Research paper thumbnail of Treatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United States

Advances in Therapy, Oct 12, 2022

Research paper thumbnail of LBMON197 Predictors Of Response To Growth Hormone Treatment In Pediatric Growth Disorders: Analysis From The Answer Program And Nordinet® IOS

Journal of the Endocrine Society

Background The American Norditropin® Studies: Web-Enabled Research (ANSWER) Program and the Nordi... more Background The American Norditropin® Studies: Web-Enabled Research (ANSWER) Program and the NordiNet® International Outcome Study (NordiNet® IOS) were large-scale, non-interventional studies intended to gather long-term data on the effectiveness and safety of Norditropin® (somatropin) treatment in the real-world setting. Data were collected in the US and Europe from 2006 to 2016. Objective To determine predictors of response to daily growth hormone (GH) for height outcomes using a longitudinal analysis across 5 years of real-world data from pediatric patients with growth hormone deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), and Prader-Willi syndrome (PWS). Methods Data were combined for ANSWER and NordiNet® IOS studies for GH-treatment-naïve pediatric patients on daily somatropin. Descriptive statistics for baseline demographics, outcomes, and GH (mg/kg/d) data were analyzed for each indication; statistics for outcome and GH data were analyzed over time for absolute ...

Research paper thumbnail of 32295 Looking beyond scalp hair loss: Factors influencing dermatologists’ assessment of alopecia areata severity

Journal of the American Academy of Dermatology

Research paper thumbnail of Probability of neutropenic-related event based on cycle 1 nadir ANC and average hemoglobin decrease at each sample

<b>Copyright information:</b>Taken from "First-cycle absolute neutrophil count c... more <b>Copyright information:</b>Taken from "First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study"Breast Cancer Research 2003;5(5):R114-R120.Published online 20 Jun 2003PMCID:PMC314422.Copyright © 2003 Rivera et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. Point estimates derived from the Silber and MDACC multiple logistic regression models. Solid line, validation model; dotted line, Silber model.

Research paper thumbnail of Comorbidities and Concomitant Medications in Dry Eye Disease

Investigative Ophthalmology & Visual Science, 2016

Research paper thumbnail of Overall survival throughout treatment course among patients diagnosed with small cell lung cancer

Journal of Clinical Oncology, 2021

e20577 Background: Previous studies have investigated overall survival (OS) among small cell lung... more e20577 Background: Previous studies have investigated overall survival (OS) among small cell lung cancer (SCLC) patients with data through 2015. Using data through mid-2019, this study strives to make the body of studies more current, and to provide more recent data on the baseline characteristics and OS of treated SCLC patients, stratified by stage at diagnosis. Methods: This retrospective cohort study identified adult patients with confirmed SCLC between January 1, 2016 - December 31, 2018 that initiated anti-cancer treatment using real-world data from electronic medical records (ConcertAI, including data from CancerLinQ, an initiative of the American Society of Clinical Oncology). Exclusion criteria included evidence of other primary cancer at baseline, no initial stage recorded, death prior to diagnosis, or participation in a clinical trial. Patients entered the cohort upon receipt of their first anti-cancer treatment after SCLC diagnosis and were assigned up to three progressio...

Research paper thumbnail of A two state capital asset pricing mode

Research paper thumbnail of Factors Associated With Response to Growth Hormone in Pediatric Growth Disorders: Results of a 5-year Registry Analysis

Journal of the Endocrine Society

Context Growth hormone (GH) therapy can increase linear growth in patients with growth hormone de... more Context Growth hormone (GH) therapy can increase linear growth in patients with growth hormone deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), and Prader-Willi syndrome (PWS), although outcomes vary by disease state. Objective To assess growth and identify factors associated with growth response with long-term GH therapy. Methods Data from pediatric patients with GHD, TS, NS, and PWS obtained at GH treatment initiation (baseline) and annually for 5 years in the ANSWER Program and NordiNet® IOS were analyzed retrospectively. Height standard deviation score (HSDS) was assessed over time, and multivariate analyses determined variables with significant positive effects on growth outcomes in each patient cohort. Results Data from patients with GHD (n = 12 683), TS (n = 1307), NS (n = 203), and PWS (n = 102) were analyzed. HSDS increased over time during GH treatment in all cohorts. Factors with significant positive effects on ΔHSDS were younger age at GH initiation and lowe...

Research paper thumbnail of LBMON197 Predictors Of Response To Growth Hormone Treatment In Pediatric Growth Disorders: Analysis From The Answer Program And Nordinet® IOS

Journal of the Endocrine Society

Background The American Norditropin® Studies: Web-Enabled Research (ANSWER) Program and the Nordi... more Background The American Norditropin® Studies: Web-Enabled Research (ANSWER) Program and the NordiNet® International Outcome Study (NordiNet® IOS) were large-scale, non-interventional studies intended to gather long-term data on the effectiveness and safety of Norditropin® (somatropin) treatment in the real-world setting. Data were collected in the US and Europe from 2006 to 2016. Objective To determine predictors of response to daily growth hormone (GH) for height outcomes using a longitudinal analysis across 5 years of real-world data from pediatric patients with growth hormone deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), and Prader-Willi syndrome (PWS). Methods Data were combined for ANSWER and NordiNet® IOS studies for GH-treatment-naïve pediatric patients on daily somatropin. Descriptive statistics for baseline demographics, outcomes, and GH (mg/kg/d) data were analyzed for each indication; statistics for outcome and GH data were analyzed over time for absolute ...

Research paper thumbnail of Prospective multi-center phase II trial of docetaxel and vinorelbine with filgrastim support in subjects with advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology, 2004

7138 Background. Although platinum based chemotherapy (CT) regimens are the standard of therapy i... more 7138 Background. Although platinum based chemotherapy (CT) regimens are the standard of therapy in first line NSCLC, a subset of patients are ineligible to receive such agents. Docetaxel and vinorelbine are each active agents in NSCLC and when combined may provide enhanced activity. The purpose of this study was to evaluate the safety and efficacy of this combination therapy when administered on a Q2W schedule with Filgrastim support. METHODS This multi-center, community based study was conducted in 10 sites that enrolled 61 CT naïve patients with Stage IIIb/IV NSCLC. Treatment consisted of vinorelbine 45mg/m2and docetaxel 60mg/m2 D1 and Filgrastim 5 mcg/kg D2 -D14 repeated Q2W for 8 cycles. Patients were evaluated for response at the end of cycles 2, 5 and 8. Confirmed response was defined as complete or partial response (CR, PR) based upon two or more evaluations, while best response was defined as the best of the three evaluations. We report response rate and Kaplan-Meier estimate (95%CL) of time to disease progression and one-year survival. RESULTS Of 61 enrolled patients 42% (95% confidence interval [CI], 30% to 54%) achieved either CR or PR as best response; and 13% (95% CI, 9% to 17%) of patients had a confirmed response. Median time to disease progression was 160 days. With a median follow-up time of 14.2 months, the estimated median survival time is 14.1 months (95% CI lower bound, 8.5), and the 1-year survival rate is 57% (95% CI, 44% to 70%). Five patients (8%) experienced febrile neutropenia (ANC < 500/mm3 plus body temperature >= 38.2°C). Overall calculated dose intensity (delivered/planned dose x 100) was 95% for vinorelbine and 93% for docetaxel. CONCLUSION The combination of docetaxel and vinorelbine can be delivered with high dose intensity with Filgrastim support. Additionally in this multi-center non-controlled study completed in a community setting, an interesting 1-year and overall median survival is observed and supports further evaluation. [Table: see text].

Research paper thumbnail of Phase II trial of R-CHOP plus maintenance rituximab for previously untreated intermediate or high grade non-Hodgkin’s lymphoma (IHGNHL) with filgrastim support for older patients greater than 60 years

Journal of Clinical Oncology, 2005

6623 Introduction: R-CHOP is considered standard treatment (tx) for IHGNHL. Administering full do... more 6623 Introduction: R-CHOP is considered standard treatment (tx) for IHGNHL. Administering full doses of R-CHOP is crucial to maximize response. Older patients (pts) may experience a higher incidenc...

Research paper thumbnail of The Association of Shift-Level Nurse Staffing With Adverse Patient Events

JONA: The Journal of Nursing Administration, 2011

Research paper thumbnail of Community-Based Trial of R-CHOP and Maintenance Rituximab for Intermediate- or High-Grade Non-Hodgkin Lymphoma with First-Cycle Filgrastim for Older Patients

Clinical Lymphoma and Myeloma, 2007

Research paper thumbnail of Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma

Cancer, 2005

Vinorelbine and docetaxel are active single agents in the treatment of nonsmall cell lung carcino... more Vinorelbine and docetaxel are active single agents in the treatment of nonsmall cell lung carcinoma (NSCLC) and may provide enhanced activity when combined in a dose-dense fashion. The efficacy and safety of this combination was assessed when it was administered every 14 days with Filgrastim support in a community practice setting. This open-label study was conducted at 12 community oncology practices in the United States. Sixty-one chemotherapy-naive patients with Stage IIIB/IV NSCLC received vinorelbine 45 mg/m2 followed by docetaxel 60 mg/m2 on Day 1 and Filgrastim 5 mcg/kg beginning on Day 2, with cycles repeated every 14 days. Among 61 enrolled patients, 44% of patients had either a complete or partial response as their best response, and 27% of patients had confirmed complete or partial responses. The median time to confirmed response was 1.9 months (95% confidence interval [95% CI], 0.9-2.3 mos), and the median duration of confirmed response was 6.0 months (95% CI, 3.1-14.4 mos). The median time to disease progression was 4.9 months (95% CI, 3.8-5.8 mos). With a median follow-up of 14.3 months, the median survival was 12.9 months (95% CI, 8.1-14.3 mos), and the 1-year survival rate was 56% (95% CI, 43-69%). The relative dose intensity was 94% for vinorelbine and 93% for docetaxel. Febrile neutropenia occurred in 9 patients (15%) and during 9 of 351 cycles (3%). It was possible to administer dose-dense vinorelbine and docetaxel chemotherapy with Filgrastim support, beginning in the first cycle, to patients with NSCLC who were treated in a community practice setting.

Research paper thumbnail of Response to “A call for consideration of needlestick injury data in evaluating staffing effectiveness”

American Journal of Infection Control, 2012

Research paper thumbnail of Needlestick injuries among nursing staff: Association with shift-level staffing

American Journal of Infection Control, 2011

Research paper thumbnail of Capacity-Building for Collecting Patient-Reported Outcomes and Experiences (PRO) Data Across Hospitals

Maternal and Child Health Journal

Purpose Patient-reported outcomes and experiences (PRO) data are an integral component of health ... more Purpose Patient-reported outcomes and experiences (PRO) data are an integral component of health care quality measurement and PROs are now being collected by many healthcare systems. However, hospital organizational capacity-building for the collection and sharing of PROs is a complex process. We sought to identify the factors that facilitated capacity-building for PRO data collection in a nascent quality improvement learning collaborative of 16 hospitals that has the goal of improving the childbirth experience. Description We used standard qualitative case study methodologies based on a conceptual framework that hypothesizes that adequate organizational incentives and capacities allow successful achievement of project milestones in a collaborative setting. The 4 project milestones considered in this study were: (1) Agreements; (2) System Design; (3) System Development and Operations; and (4) Implementation. To evaluate the success of reaching each milestone, critical incidents were...

Research paper thumbnail of Factors Associated With Response to Growth Hormone in Pediatric Growth Disorders: Results of a 5-year Registry Analysis

Journal of the Endocrine Society

Context Growth hormone (GH) therapy can increase linear growth in patients with growth hormone de... more Context Growth hormone (GH) therapy can increase linear growth in patients with growth hormone deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), and Prader-Willi syndrome (PWS), although outcomes vary by disease state. Objective To assess growth and identify factors associated with growth response with long-term GH therapy. Methods Data from pediatric patients with GHD, TS, NS, and PWS obtained at GH treatment initiation (baseline) and annually for 5 years in the ANSWER Program and NordiNet® IOS were analyzed retrospectively. Height standard deviation score (HSDS) was assessed over time, and multivariate analyses determined variables with significant positive effects on growth outcomes in each patient cohort. Results Data from patients with GHD (n = 12 683), TS (n = 1307), NS (n = 203), and PWS (n = 102) were analyzed. HSDS increased over time during GH treatment in all cohorts. Factors with significant positive effects on ΔHSDS were younger age at GH initiation and lowe...

Research paper thumbnail of Reporting of Adverse Drug Reactions with Parenteral Drugs for the On-Demand Treatment of Hereditary Angioedema Attacks – Analysis of the FAERS Database 2009 to 2022

Journal of Allergy and Clinical Immunology

Research paper thumbnail of The Association of Alopecia Areata-Related Emotional Symptoms with Work Productivity and Daily Activity Among Patients with Alopecia Areata

Research paper thumbnail of Treatment Patterns and Treatment Satisfaction Among Adults with Alopecia Areata in the United States

Advances in Therapy, Oct 12, 2022

Research paper thumbnail of LBMON197 Predictors Of Response To Growth Hormone Treatment In Pediatric Growth Disorders: Analysis From The Answer Program And Nordinet® IOS

Journal of the Endocrine Society

Background The American Norditropin® Studies: Web-Enabled Research (ANSWER) Program and the Nordi... more Background The American Norditropin® Studies: Web-Enabled Research (ANSWER) Program and the NordiNet® International Outcome Study (NordiNet® IOS) were large-scale, non-interventional studies intended to gather long-term data on the effectiveness and safety of Norditropin® (somatropin) treatment in the real-world setting. Data were collected in the US and Europe from 2006 to 2016. Objective To determine predictors of response to daily growth hormone (GH) for height outcomes using a longitudinal analysis across 5 years of real-world data from pediatric patients with growth hormone deficiency (GHD), Turner syndrome (TS), Noonan syndrome (NS), and Prader-Willi syndrome (PWS). Methods Data were combined for ANSWER and NordiNet® IOS studies for GH-treatment-naïve pediatric patients on daily somatropin. Descriptive statistics for baseline demographics, outcomes, and GH (mg/kg/d) data were analyzed for each indication; statistics for outcome and GH data were analyzed over time for absolute ...

Research paper thumbnail of 32295 Looking beyond scalp hair loss: Factors influencing dermatologists’ assessment of alopecia areata severity

Journal of the American Academy of Dermatology

Research paper thumbnail of Probability of neutropenic-related event based on cycle 1 nadir ANC and average hemoglobin decrease at each sample

<b>Copyright information:</b>Taken from "First-cycle absolute neutrophil count c... more <b>Copyright information:</b>Taken from "First-cycle absolute neutrophil count can be used to improve chemotherapy-dose delivery and reduce the risk of febrile neutropenia in patients receiving adjuvant therapy: a validation study"Breast Cancer Research 2003;5(5):R114-R120.Published online 20 Jun 2003PMCID:PMC314422.Copyright © 2003 Rivera et al., licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL. Point estimates derived from the Silber and MDACC multiple logistic regression models. Solid line, validation model; dotted line, Silber model.

Research paper thumbnail of Comorbidities and Concomitant Medications in Dry Eye Disease

Investigative Ophthalmology & Visual Science, 2016

Research paper thumbnail of Overall survival throughout treatment course among patients diagnosed with small cell lung cancer

Journal of Clinical Oncology, 2021

e20577 Background: Previous studies have investigated overall survival (OS) among small cell lung... more e20577 Background: Previous studies have investigated overall survival (OS) among small cell lung cancer (SCLC) patients with data through 2015. Using data through mid-2019, this study strives to make the body of studies more current, and to provide more recent data on the baseline characteristics and OS of treated SCLC patients, stratified by stage at diagnosis. Methods: This retrospective cohort study identified adult patients with confirmed SCLC between January 1, 2016 - December 31, 2018 that initiated anti-cancer treatment using real-world data from electronic medical records (ConcertAI, including data from CancerLinQ, an initiative of the American Society of Clinical Oncology). Exclusion criteria included evidence of other primary cancer at baseline, no initial stage recorded, death prior to diagnosis, or participation in a clinical trial. Patients entered the cohort upon receipt of their first anti-cancer treatment after SCLC diagnosis and were assigned up to three progressio...

Research paper thumbnail of A two state capital asset pricing mode